The FDA wants to pull its approval of a drug. It’s not so easy.
The US Food and Drug Administration is seeking to withdraw Tavneos, a treatment for a rare form of vasculitis, after concluding that the pivotal trial may have involved manipulated data and that the drug lacks substantial evidence of effectiveness. The dispute matters because patients and some doctors regard it as a useful option, while the drug has been linked to serious liver injuries and costs about $220,000 a year.
The FDA approved Tavneos in 2021 after an advisory committee narrowly recommended approval, despite concerns about the trial’s design and uncertain results. Amgen, which acquired the drug’s developer ChemoCentryx, argues that the total evidence supports keeping it available; meanwhile, the trial paper has been retracted and the drug is being removed in Europe and the UK. US regulators still have to decide its fate, amid wider questions about how drug trial data are checked and how effectiveness is established.
In short
- FDA seeks to withdraw Tavneos over trial data and safety concerns.
- Amgen says the treatment should remain available.
- The drug’s US future remains undecided.
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Keeping Tavneos available preserves an additional treatment option for people with a rare, serious disease, particularly if some patients and doctors have seen practical benefit. Amgen argues that the broader body of evidence supports its effectiveness, and withdrawing an approved drug is consequential when patients have few alternatives; regulators should weigh the full record carefully and apply a fair process.
The case against
The FDA’s case is that approval requires substantial, reliable evidence of effectiveness, and doubts about possible trial data manipulation undermine confidence in the pivotal study. With reported serious liver injuries and an annual cost of about $220,000, continuing access may expose patients and the health system to significant risks and expense without sufficiently established benefit; removal in Europe and the UK adds to the case for reassessment.
Explained simply
Vasculitis is inflammation of blood vessels, which can damage organs. Tavneos is a medicine approved in the US in 2021 for a rare form of the disease; the FDA, the agency that regulates medicines, approved it after a close advisory committee vote despite questions about the main trial’s design and results.
The FDA now says the trial may have involved manipulated data and that there is not strong enough evidence the drug works. Amgen, which bought Tavneos’s original developer, says the wider evidence supports keeping it available. Patients and some doctors see it as a useful option, while serious liver injuries have also been linked to the medicine.
The case raises questions about how regulators check trial data and judge whether a medicine is effective. Tavneos is being withdrawn in Europe and the UK, but its status in the US remains for regulators to decide; it also costs about $220,000 a year.
Health Medicine Research Science